Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly logo

Allergen immunotherapy: safety, first‑dose rules, and evidence

Introduction

Allergen immunotherapy (AIT) modifies the immune response to inhalant allergens and remains the only disease‑modifying treatment for allergic rhinitis/rhinoconjunctivitis (and selected asthma phenotypes) in appropriate patients. This explainer summarizes safety requirements, first‑dose supervision rules, product status in the United States, pediatric use, and contraindications for these therapies.

Immunotherapy modalities and safety profile

  • Subcutaneous immunotherapy (SCIT, “allergy shots”)

  • Evidence: Effective for aeroallergens with durable benefit after 3–5 years of maintenance.

  • Safety: Systemic reactions are uncommon but can be serious; most occur within 30 minutes post‑injection. U.S. surveillance estimates life‑threatening reactions at ~0.005% of patients (≈1 per 160,000 injection visits), with fatalities now rarer than historic estimates thanks to risk mitigation. Patients must remain under observation for at least 30 minutes after each injection and clinics must be prepared to treat anaphylaxis.

  • Sublingual immunotherapy (SLIT)

  • Two distinct forms in the U.S.:

  • FDA‑approved single‑allergen tablets (for timothy/cross‑reactive grasses, 5‑grass mix, short ragweed, and house dust mite). Tablets have a favorable safety profile relative to SCIT but still carry a boxed warning for anaphylaxis; first dose must be supervised in a medical setting and an epinephrine autoinjector is prescribed for home use.

  • Liquid SLIT “drops” (multi‑allergen mixtures): not FDA‑approved for respiratory allergy in the U.S.; use is off‑label. Major U.S. societies note this status and limit formal recommendations accordingly.

First‑dose supervision and epinephrine requirements (SLIT tablets)

  • Location and monitoring: The very first tablet dose must be administered under healthcare supervision with the capability to manage anaphylaxis; observe for ≥30 minutes before discharge. Subsequent doses are taken at home. This requirement is stated in each FDA PI and reiterated by professional allergy societies.

  • Epinephrine: Prescribe an epinephrine autoinjector, teach recognition of systemic reactions, and instruct immediate use and urgent evaluation if symptoms occur. This is explicit in each tablet PI.

FDA‑approved SLIT tablets: indications, ages, and key label notes

As of February 27, 2025 (FDA approval date expanding Odactra’s age range), U.S. approvals include:

  • Grastek (timothy grass; cross‑reactive grasses): ages 5–65; daily tablet; first dose supervised; epinephrine prescribed.

  • Oralair (5‑grass mix: sweet vernal, orchard, perennial rye, timothy, Kentucky blue): ages 5–65; pre‑/co‑seasonal dosing; first dose supervised; epinephrine prescribed.

  • Ragwitek (short ragweed): ages 5–65; seasonal dosing; first dose supervised; epinephrine prescribed.

  • Odactra (house dust mite): ages 5–65; year‑round dosing; first dose supervised; epinephrine prescribed; age range expanded to 5–65 on Feb 27, 2025.

Off‑label status of SLIT “drops” in the U.S.

  • No liquid SLIT extract has FDA approval for respiratory allergy. U.S. guidance explains that liquid SLIT is off‑label; efficacy evidence is strongest for single‑allergen products, and dosing standards for multi‑allergen mixtures are not established under U.S. regulation. Coverage by insurers is uncommon.

Pediatric use (ages ≥5 years)

  • All four FDA‑approved tablets are authorized down to age 5. Pediatric dosing and supervision mirror adult rules, with an adult administering and observing each home dose for children.

Contraindications and when to avoid or defer AIT

  • SLIT tablets (per PIs and society guidance):

  • Absolute: severe, unstable, or uncontrolled asthma; history of severe systemic reaction to any immunotherapy; history of severe local reaction to SLIT; history of eosinophilic esophagitis (EoE); hypersensitivity to excipients.

  • Relative/clinical cautions: concomitant beta‑blocker use (reduced epinephrine responsiveness), medical conditions reducing ability to survive anaphylaxis, and inability to correctly use an autoinjector.

  • SCIT: defer in uncontrolled asthma or during acute respiratory infections/exacerbations; observe 30 minutes post‑injection at each visit.

  • Pregnancy: do not initiate AIT during pregnancy, but continuation at a stable dose can be considered if well‑tolerated prior to conception.

Evidence synthesis: SCIT vs SLIT

  • Effectiveness: Both SCIT and SLIT are effective for allergic rhinitis/rhinoconjunctivitis; network meta‑analyses and practice parameters conclude broadly comparable symptom control when using standardized products for the relevant allergen.

  • Safety: SLIT has fewer systemic reactions than SCIT; however, tablets carry boxed warnings and require first‑dose supervision with epinephrine on hand.

  • Convenience: SLIT tablets are taken at home after the first supervised dose; SCIT requires in‑office dosing and observation at each visit.

Practical checklist for SLIT tablets (clinician and patient)

  • Before prescribing: confirm IgE‑mediated sensitization (skin test or specific IgE) to the target allergen; screen for contraindications (especially uncontrolled asthma and EoE); assess ability to use epinephrine.

  • First dose: administer in clinic with ≥30‑minute observation; review anaphylaxis action plan.

  • Home use: daily dosing as labeled; avoid eating/drinking for at least 1 minute after tablet placement (per PI specifics); maintain epinephrine access; pause dosing and seek guidance after oral/esophageal symptoms, febrile illness, dental procedures, or missed doses per PI.

  • Duration: typically 3 years (pre/co‑seasonal for grass/ragweed tablets; continuous for dust mite) to achieve durable benefit.

References (selected)

  • FDA product pages and PIs: Grastek • Oralair • Ragwitek • Odactra • FDA announcement on Odactra’s pediatric expansion.

  • AAAAI/ACAAI guidance: Allergy tablets (AAAAI) • SLIT patient summary (AAAAI/ACAAI) • Allergy shots (AAAAI) • Pregnancy & AIT.

  • Comparative effectiveness/safety: Surveillance study of AIT reactions • SLIT practice parameter update (2017) • AAAAI SLIT overview.

FAQ

  • What ages are eligible for FDA‑approved SLIT tablets?

  • All four tablets (Grastek, Oralair, Ragwitek, Odactra) are approved for ages 5–65; Odactra’s lower age was extended on February 27, 2025.

  • Do I need an epinephrine autoinjector for SLIT tablets?

  • Yes. Tablets carry a boxed warning; an autoinjector must be prescribed and you must be trained to use it. First dose is supervised in clinic.

  • Are liquid SLIT “drops” FDA‑approved in the U.S.?

  • No. Liquid SLIT for respiratory allergens is off‑label in the U.S.

  • Who should not start immunotherapy?

  • Uncontrolled asthma, EoE (for SLIT), prior severe reaction to AIT, inability to use epinephrine, or significant comorbidities that raise risk from anaphylaxis. See PI contraindications and society guidance above.

  • How long does treatment last?

  • Typical course is about 3 years. Grass/ragweed tablets are pre‑/co‑seasonal; dust‑mite tablet is continuous. SCIT courses are usually 3–5 years.

Structured data (FAQ schema)